المؤلفون: Fabio Demontis, Liam C. Hunt

المصدر: J Gerontol A Biol Sci Med Sci

مصطلحات موضوعية: chemistry.chemical_classification, THE JOURNAL OF GERONTOLOGY: Biological Sciences, Aging, medicine.medical_specialty, L-Lactate Dehydrogenase, Chemistry, Longevity, Skeletal muscle, chemistry.chemical_compound, Endocrinology, medicine.anatomical_structure, Enzyme, Anaerobic glycolysis, Internal medicine, Age related, Lactate dehydrogenase, medicine, Animals, Drosophila, Glycolysis, NAD+ kinase, Geriatrics and Gerontology, Muscle, Skeletal, Phosphofructokinase

الوصف: Metabolic adaptations occur with aging but the significance and causal roles of such changes are only partially known. In Drosophila, we find that skeletal muscle aging is paradoxically characterized by increased readouts of glycolysis (lactate, NADH/NAD+) but reduced expression of most glycolytic enzymes. This conundrum is explained by lactate dehydrogenase (LDH), an enzyme necessary for anaerobic glycolysis and whose expression increases with aging. Experimental Ldh overexpression in skeletal muscle of young flies increases glycolysis and shortens life span, suggesting that age-related increases in muscle LDH contribute to mortality. Similar results are also found with overexpression of other glycolytic enzymes (Pfrx/PFKFB, Pgi/GPI). Conversely, hypomorphic mutations in Ldh extend life span, whereas reduction in PFK, Pglym78/PGAM, Pgi/GPI, and Ald/ALDO levels shorten life span to various degrees, indicating that glycolysis needs to be tightly controlled for optimal aging. Altogether, these findings indicate a role for muscle LDH and glycolysis in aging.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eda58c557e576945dfeec15071663e76Test
https://doi.org/10.1093/gerona/glab260Test

المؤلفون: Hiroki Yamada, Shin Egawa, Kenichi Hata, Yusuke Koike, Masaya Murakami, Hiroshi Nakajo, Hirokazu Abe, Takehito Naruoka, Wataru Fukuokaya, Shunsuke Tsuzuki, Jun Miki, Kazuki Nishimura, Kojiro Tashiro, Shota Kawano, Taizo Uchimoto, Shingo Sugaya, Yusuke Yano, Daisuke Watanabe, Hideomi Nishikawa, Masayuki Tomita, Takahiro Kimura, Haruhisa Koide, Keiichiro Mori

المصدر: Japanese Journal of Clinical Oncology. 51:1665-1671

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Androgen deprivation therapy, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Lactate dehydrogenase, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Retrospective Studies, L-Lactate Dehydrogenase, Proportional hazards model, business.industry, Hazard ratio, Prostatic Neoplasms, Androgen Antagonists, Retrospective cohort study, General Medicine, Alkaline Phosphatase, Prognosis, medicine.disease, Hormones, Androgen receptor, Prostatic Neoplasms, Castration-Resistant, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Alkaline phosphatase, business

الوصف: Background Randomized trials showed the survival benefits of the combined use of androgen receptor axis-targeted agents with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer (mHSPC), regardless of the risk. However, treating patients with low-risk mHSPC with such intensive treatment is still debatable. Methods This retrospective study included 155 low-risk patients among 467 mHSPC patients treated in our affiliated institutions. The association between predictive factors and treatment outcomes was estimated using the Kaplan–Meier method and log-rank test. Predictive factors for castration resistant prostate cancer (CRPC)-free survival were investigated using Cox regression analyses. Results During the median follow-up of 39 months, 38.7% of patients developed CRPC and 14.2% died. In the multivariate analyses, a presence of Gleason pattern 5 (hazard ratio [HR] 2.04), high alkaline phosphatase (HR 1.007) and high lactate dehydrogenase (HR 1.009) were significant predictive factors for shorter CRPC-free survival. Finally, 155 patients were stratified into favorable- and unfavorable-risk groups based on the numbers of the predictive factors. The overall survival (OS) in the unfavorable-risk group (total scores: 2–3) was significantly worse than that of the favorable-risk group (total score: 0–1) (P = 0.02). This prognostic model was assessed with 50 low-risk mHSPC patients from the external validation dataset and found both the time to CRPC, and the OS in the unfavorable-risk group was significantly worse than that of the favorable-risk group (P Conclusions The combination of Gleason pattern 5, high alkaline phosphatase and lactate dehydrogenase can predict those with worse OS in low-risk mHSPC patients.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ca64e70eea9e33e609c75690030a9f6Test
https://doi.org/10.1093/jjco/hyab115Test

المؤلفون: Yasutomo Nakai, Motokiyo Komiyama, Naohisa Kusakabe, Motohide Uemura, Mikio Sugimoto, Satoshi Anai, Keita Tamura, Nobuo Shinohara, Kosuke Ueda, Ken Tanaka, Keita Minami, Kojiro Ohba, Tetsuya Shindo, Michinobu Ozawa, Naoki Kohei, Toshihiro Suzuki, Takahiro Osawa, Hideaki Miyake, Ario Takeuchi, Akira Yokomizo

المصدر: Japanese Journal of Clinical Oncology. 51:810-818

مصطلحات موضوعية: Male, Oncology, Cancer Research, medicine.medical_specialty, Axitinib, medicine.medical_treatment, Urologic Oncology, Antineoplastic Agents, Targeted therapy, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Japan, Risk Factors, Renal cell carcinoma, Albumins, Lactate dehydrogenase, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, Carcinoma, Renal Cell, Aged, L-Lactate Dehydrogenase, biology, business.industry, C-reactive protein, Albumin, Cancer, General Medicine, Middle Aged, Prognosis, medicine.disease, Kidney Neoplasms, C-Reactive Protein, chemistry, 030220 oncology & carcinogenesis, biology.protein, Female, business, medicine.drug

الوصف: Purpose To externally validate the utility of the albumin, C-reactive protein and lactate dehydrogenase model to predict the overall survival of previously treated metastatic renal cell carcinoma patients. Patients and methods The ability of the albumin, C-reactive protein and lactate dehydrogenase model to predict overall survival was validated and compared with those of other prognostication models using data from 421 metastatic renal cell carcinoma patients receiving second-line axitinib therapy at 36 hospitals belonging to the Japan Urologic Oncology Group. Results The following factors in this cohort were independently associated with poor overall survival in a multivariate analysis: a low Karnofsky performance status, 50%. The superiority of the albumin, C-reactive protein and lactate dehydrogenase model to the Memorial Sloan Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium models, but not the Japan Urologic Oncology Group model, was demonstrated by multiple statistical analyses. Conclusions The utility of the albumin, C-reactive protein and lactate dehydrogenase model as a simple and objective prognostication tool was successfully validated using data from 421 metastatic renal cell carcinoma patients receiving second-line axitinib.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bbf92a5720e1bd1b2933673aa01ae3dTest
https://doi.org/10.1093/jjco/hyaa264Test

المؤلفون: Salvador Payán‐Pernía, Silvana Ana Rina Novelli Canales, Ángel F. Remacha Sevilla, Lucía Gómez Pérez, Jordi Sierra Gil

المصدر: Laboratory Medicine

مصطلحات موضوعية: Male, 0301 basic medicine, medicine.medical_treatment, Clinical Biochemistry, Labmed/1010, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, 030212 general & internal medicine, Hematology, biology, hematology, Area under the curve, Middle Aged, C-Reactive Protein, Breathing, Female, AcademicSubjects/MED00690, Adult, medicine.medical_specialty, Science, mechanical ventilation, Young Adult, 03 medical and health sciences, Internal medicine, Lactate dehydrogenase, medicine, Humans, Lymphocyte Count, Aged, Retrospective Studies, Biochemistry, medical, Mechanical ventilation, L-Lactate Dehydrogenase, Surrogate endpoint, business.industry, ferritin, Biochemistry (medical), C-reactive protein, COVID-19, biomarkers, lactate dehydrogenase, Respiration, Artificial, Ferritin, Logistic Models, 030104 developmental biology, chemistry, Ferritins, biology.protein, business

الوصف: Objective Early detection of patients with COVID-19 who will need mechanical invasive ventilation (MIV) may aid in delivering proper care and optimizing the use of limited resources. Methods In this single-center retrospective observational study, we aimed to identify simple laboratory parameters that in combination with ferritin (a surrogate marker of severe inflammation) may help predict early (first 48 hours) MIV. A total of 160 patients with COVID-19 in whom serum ferritin, absolute lymphocyte count (ALC), platelet count, C-reactive protein (CRP), and lactate dehydrogenase (LDH) had been analyzed at admission were included. Results We found that ferritin, LDH, ALC, and CRP predicted with 88% accuracy the probability of early MIV. Results indicated that LDH showed the greater area under the curve (AUC), with a value of 89.1%. Using the AUC, we established cutoff values for clinical application. Finally, we developed a classification tree based on LDH for its clinical use. Conclusion Ferritin, LDH, ALC, and CRP predict with 88% accuracy the probability of early MIV.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe250af5ec4d7b612e8fc0033bcc207Test
https://doi.org/10.1093/labmed/lmaa105Test

المؤلفون: Ping Wang, Adam Bagg, Daniel S. Herman, Esmeralda Toro, Ezra Baraban

المصدر: The Journal of Applied Laboratory Medicine. 4:433-438

مصطلحات موضوعية: Blood Specimen Collection, medicine.medical_specialty, Hematology, L-Lactate Dehydrogenase, Chemistry, Transportation, Dehydrogenase, General Medicine, Blood Physiological Phenomena, medicine.disease, Hemolysis, Pneumatic tube, Specimen Handling, Andrology, chemistry.chemical_compound, Increased plasma lactate, Internal medicine, Lactate dehydrogenase, medicine, Humans, Platelet, Ldh activity, Blood Chemical Analysis

الوصف: Background: Lactate dehydrogenase (LDH) is a nonspecific biomarker for diseases including lymphoma. Serum and plasma are generally considered interchangeable for LDH testing. Investigation into falsely increased plasma LDH concentration results led to the hypothesis that a workflow change that included pneumatic tube system (PTS) transportation caused the errors. The following study was conducted to test the hypothesis. Methods: Plasma and serum separator tube samples were each drawn in duplicate, centrifuged, transported either through the PTS or by hand courier, and evaluated by means of clinical chemistry and hematology assays. Smear slides were made out of the plasma and examined. Aggregate patient results before and after the PTS workflow change were compared. Results: In post-PTS plasma samples, LDH activity was 26%–149% higher. Similarly, white blood cells (WBCs) were 14- to 156-fold higher and platelets were 1- to 13-fold higher. Smear examination revealed dramatically more cells and cell fragments. No significant hemolysis was observed in plasma by chemistry hemolysis indices or hemoglobin testing. These effects were not observed in similarly transported serum samples in gel separator tubes. Aggregate LDH patient results, including moving medians, demonstrated dramatic changes following PTS workflow implementation. Conclusions: PTS transportation led to falsely increased LDH concentration in plasma. These LDH concentration elevations are not heralded by standard indicators of hemolysis. These errors can be prevented by restricting LDH concentration testing to serum collected in gel separator tubes. Moving patient statistics can effectively detect important testing process changes not revealed by external QC or indices.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f66ab5e6094e70dd8d0998b44f3898Test
https://doi.org/10.1373/jalm.2018.028928Test

المؤلفون: Hao-Long Zeng, Dao-Yuan Yue, Wei Liu, Xu Wang, Huijun Li, Hao Li, Qing Yang, Leike Zhang, Qing-Bin Lu

المصدر: Clinical Infectious Diseases
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

مصطلحات موضوعية: Microbiology (medical), China, medicine.medical_specialty, fatal outcome, media_common.quotation_subject, Lymphocyte, medicine.medical_treatment, 030204 cardiovascular system & hematology, Procalcitonin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Lactate dehydrogenase, Major Article, medicine, Humans, 030212 general & internal medicine, Stage (cooking), Aged, Retrospective Studies, media_common, SARS-CoV-2, business.industry, Convalescence, COVID-19, Retrospective cohort study, Prognosis, AcademicSubjects/MED00290, Infectious Diseases, medicine.anatomical_structure, Cytokine, chemistry, Cohort, Laboratories, business

الوصف: Background Patients with coronavirus disease 2019 (COVID-19) experience a wide clinical spectrum, with over 2% developing fatal outcome. The prognostic factors for fatal outcome remain sparsely investigated. Methods A retrospective cohort study was performed in a cohort of patients with confirmed COVID-19 in one designated hospital in Wuhan, China, from 17 January–5 March 2020. The laboratory parameters and a panel of cytokines were consecutively evaluated until patients’ discharge or death. The laboratory features that could be used to predict fatal outcome were identified. Results Consecutively collected data on 55 laboratory parameters and cytokines from 642 patients with COVID-19 were profiled along the entire disease course, based on which 3 clinical stages (acute stage, days 1–9; critical stage, days 10–15; and convalescence stage, day 15 to observation end) were determined. Laboratory findings based on 75 deceased and 357 discharged patients revealed that, at the acute stage, fatality could be predicted by older age and abnormal lactate dehydrogenase (LDH), urea, lymphocyte count, and procalcitonin (PCT) level. At the critical stage, the fatal outcome could be predicted by age and abnormal PCT, LDH, cholinesterase, lymphocyte count, and monocyte percentage. Interleukin 6 (IL-6) was remarkably elevated, with fatal cases having a more robust production than discharged cases across the whole observation period. LDH, PCT, lymphocytes, and IL-6 were considered highly important prognostic factors for COVID-19–related death. Conclusions The identification of predictors that were routinely tested might allow early identification of patients at high risk of death for early aggressive intervention.
A full description of the laboratory abnormalities for coronavirus disease 2019 (COVID-19) is reported, based on which 3 clinical stages of the disease were defined and their application in predicting fatal COVID-19 was explored.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2163d2c2ae76a6d6b671b8a315c679f7Test
https://doi.org/10.1093/cid/ciaa574Test

المؤلفون: Asal Seraji, Sajad Yaghoubi, Mohammad Parohan

المصدر: European Heart Journal. Acute Cardiovascular Care

مصطلحات موضوعية: medicine.medical_specialty, Heart Injury, Heart Diseases, Pneumonia, Viral, 030204 cardiovascular system & hematology, Cochrane Library, Critical Care and Intensive Care Medicine, Creatine, Gastroenterology, Betacoronavirus, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, systematic review, Internal medicine, Lactate dehydrogenase, medicine, Creatine Kinase, MB Form, Humans, heart injury, 030212 general & internal medicine, Pandemics, biology, SARS-CoV-2, business.industry, Myocardium, Troponin I, COVID-19, General Medicine, Confidence interval, meta-analysis, Observational Studies as Topic, chemistry, Meta-analysis, biology.protein, Creatine kinase, Observational study, Coronavirus Infections, Cardiology and Cardiovascular Medicine, business, Biomarkers

الوصف: Coronavirus disease 2019 (COVID-19) is a global pandemic impacting 213 countries/territories and more than 5,934,936 patients worldwide. Cardiac injury has been reported to occur in severe and death cases. This meta-analysis was done to summarize available findings on the association between cardiac injury and severity of COVID-19 infection. Online databases including Scopus, PubMed, Web of Science, Cochrane Library and Google Scholar were searched to detect relevant publications up to 20 May 2020, using relevant keywords. To pool data, a fixed- or random-effects model was used depending on the heterogeneity between studies. In total, 22 studies with 3684 COVID-19 infected patients (severe cases=1095 and death cases=365) were included in this study. Higher serum levels of lactate dehydrogenase (weighted mean difference (WMD) =108.86 U/L, 95% confidence interval (CI)=75.93–141.79, p

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8941056ae703bbbf956fe013c4fa3025Test
https://doi.org/10.1177/2048872620937165Test

المؤلفون: Jean A. Yared, Elizabeth Hutnick, Ashraf Badros, Mehmet H. Kocoglu, Nancy M. Hardy, Forat Lutfi, Søren M. Bentzen, Jonathan Siglin, Aaron P. Rapoport, Firas El Chaer, Carl Shanholtz, Kathleen Ruehle, Vivek Kesari, Noa G. Holtzman, Hao Xie, Haroon Ahmad, Saurabh Dahiya, Ali Bukhari, Natalie Gahres

المصدر: Neuro Oncol

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Clinical Investigations, Cell- and Tissue-Based Therapy, Fibrinogen, Immunotherapy, Adoptive, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Lactate dehydrogenase, Humans, Medicine, Receptors, Chimeric Antigen, business.industry, Common Terminology Criteria for Adverse Events, Immunotherapy, medicine.disease, Chimeric antigen receptor, Lymphoma, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, Toxicity, Neurotoxicity Syndromes, Chimeric Antigen Receptor T-Cell Therapy, Neurology (clinical), business, Biomarkers, medicine.drug

الوصف: Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associated neurotoxicity syndrome (ICANS), is poorly understood. To better elucidate the clinical characteristics, treatment outcomes, and correlative biomarkers of ICANS, we review here a single-center analysis of ICANS after CAR T-cell therapy in R/R LBCL. Methods Patients (n = 45) with R/R LBCL treated with axicabtagene ciloleucel (axi-cel) were identified. Data regarding treatment course, clinical outcomes, and correlative studies were collected. Patients were monitored and graded for ICANS via CARTOX-10 scoring and Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria, respectively. Results Twenty-five (56%) patients developed ICANS, 18 (72%) of whom had severe (CTCAE grades 3–4) ICANS. Median time to development of ICANS was 5 days (range, 3–11). Elevated pre-infusion (day 0 [D0]) fibrinogen (517 vs 403 mg/dL, upper limit of normal [ULN] 438 mg/dL, P = 0.01) and D0 lactate dehydrogenase (618 vs 506 units/L, ULN 618 units/L, P = 0.04) were associated with ICANS. A larger drop in fibrinogen was associated with ICANS (393 vs 200, P < 0.01). Development of ICANS of any grade had no effect on complete remission (CR), progression-free survival (PFS), or overall survival (OS). Duration and total dose of steroid treatment administered for ICANS did not influence CR, PFS, or OS. Conclusions ICANS after CAR-T with axi-cel for R/R LBCL was seen in about half of patients, the majority of which were high grade. Contrary to previous reports, neither development of ICANS nor its treatment were associated with inferior CR, PFS, or OS. The novel finding of high D0 fibrinogen level can identify patients at higher risk for ICANS.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b1182b0bb73f160ad29f057ff771a3cTest
https://doi.org/10.1093/neuonc/noaa183Test

المؤلفون: Cozie Gwaikolo, Eric Adu, Roa Harb, John Ssentamu, Callum Patrick Swift, Ian Wachekwa, Mukhtar A Adeiza

المصدر: American Journal of Clinical Pathology. 152:86-90

مصطلحات موضوعية: medicine.medical_specialty, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Cerebrospinal fluid, Peritoneum, Albumins, Lactate dehydrogenase, Internal medicine, medicine, Humans, Total protein, Body fluid, L-Lactate Dehydrogenase, business.industry, Albumin, Proteins, General Medicine, Mixing study, Liberia, Body Fluids, Glucose, medicine.anatomical_structure, chemistry, 030220 oncology & carcinogenesis, Effect study, business, 030215 immunology

الوصف: OBJECTIVES To apply a simple method to validate testing for albumin, glucose, lactate dehydrogenase (LDH) and total protein (TP) in peritoneal, pleural, and cerebrospinal fluids (CSF) at a hospital in Liberia. METHODS Serum and body fluid specimens were mixed to create 100% serum and 25%, 50%, 75%, and 100% fluid tubes, which were tested on a Biotecnica BT3500. Differences less than 10% between calculated and measured concentrations were considered acceptable. RESULTS The means (confidence intervals) of the percent differences were: albumin/peritoneal 12.8 (6.0-19.7), albumin/pleural 2.8 (1.3-4.2), albumin/CSF 4.8 (2.2-7.5), glucose/peritoneal 4.0 (1.9-6.0), glucose/pleural 4.4 (3.1-5.7), glucose/CSF 2.9 (1.8-4.0), LDH/peritoneal 9.5 (6.3-12.7), LDH/pleural 9.5 (5.4-13.6), LDH/CSF 9.2 (5.2-13.3), TP/peritoneal 7.6 (3.8-11.4), TP/pleural 3.8 (1.5-6.2), and TP/CSF 4.5 (1.0-8.1). CONCLUSIONS All mean differences except for one were less than 10%, allowing for the adoption of clinical testing. The mixing study is a low-cost method for quality-assured testing that can be performed by resource-limited laboratories.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::476ab83fcabd4051fba64de25b5c1383Test
https://doi.org/10.1093/ajcp/aqz027Test

المؤلفون: Shimpei Anami, K. Fukuda, Masahiro Inada, Yasumasa Nishimura, Kazuki Ishikawa, Takuya Uehara, Shuichi Kanamori, Kiyoshi Nakamatsu, Hiroshi Doi, Yutaro Wada

المصدر: Journal of Radiation Research

مصطلحات موضوعية: Male, 0301 basic medicine, medicine.medical_specialty, Lung Neoplasms, Health, Toxicology and Mutagenesis, medicine.medical_treatment, predictor, Asymptomatic, Gastroenterology, whole-brain radiotherapy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Lactate dehydrogenase, Regular Paper, small-cell lung cancer, Humans, Medicine, brain metastasis, Radiology, Nuclear Medicine and imaging, Carcinoma, Small Cell, Lung cancer, Lactate Dehydrogenases, Aged, Aged, 80 and over, Univariate analysis, Radiation, Brain Neoplasms, business.industry, Hazard ratio, lactate dehydrogenase, Middle Aged, medicine.disease, Survival Analysis, Confidence interval, Radiation therapy, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, Multivariate Analysis, Female, medicine.symptom, business, Brain metastasis

الوصف: This study aimed to identify factors that predict prognosis after radiotherapy for brain metastases (BMs) from small-cell lung cancer (SCLC). This study retrospectively evaluated 48 consecutive patients who underwent whole-brain radiotherapy (WBRT) for BMs from SCLC between February 2008 and December 2017. WBRT was delivered at a median dose of 30 Gy (range: 30–40 Gy) in 10 fractions (range: 10–16 fractions). Clinical factors were tested for associations with overall survival after WBRT. The median survival and 1-year overall survival rate after WBRT treatment were 232 days and 34.4%, respectively. Univariate analyses revealed that longer survival was associated with Eastern Cooperative Oncology Group performance status of 0–1, asymptomatic BMs, lactate dehydrogenase (LDH) in the normal range, Radiation Therapy Oncology Group–recursive partitioning analysis class 2, and a graded prognostic assessment score of ≥1.5 (P < 0.01, P < 0.01, P < 0.01, P < 0.01 and P < 0.05, respectively). In the multivariate analyses, longer survival was independently associated with asymptomatic BMs [hazard ratio for death (HR), 0.32; 95% confidence interval (CI), 0.12–0.79; P < 0.05] and LDH in the normal range (HR, 0.42; 95% CI, 0.21–0.83; P < 0.05). The presence of symptoms due to BMs and LDH values independently predicted prognosis after WBRT for BMs from SCLC. Elevated LDH may provide valuable information for identifying patients with BMs who could have poor survival outcomes.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fee33272396d4e99063ae052f0171151Test
https://doi.org/10.1093/jrr/rry107Test